Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Intellia Therapeutics, Inc.    NTLA

INTELLIA THERAPEUTICS, INC.

(NTLA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Intellia Therapeutics : Shares Up 15% After Regeneron Expands Collaboration

share with twitter share with LinkedIn share with facebook
06/01/2020 | 10:41am EDT

By Chris Wack

 

Intellia Therapeutics Inc. shares were up 15% to $20.14 after Regeneron Pharmaceuticals Inc. expanded their collaboration to provide Regeneron with rights to develop products for additional in vivo CRISPR/Cas9-based therapeutic targets and for the companies to jointly develop potential products for the treatment of hemophilia A and B.

The companies said Regeneron will receive non-exclusive rights to independently develop and commercialize ex vivo gene-edited products.

Intellia will receive an upfront payment of $70 million, and Regeneron will make an additional equity investment in Intellia of $30 million at $32.42 a share.

Under the amended agreement, the companies will extend their collaboration until April 2024, with Regeneron having an option to renew for an additional two years. Regeneron will have rights to discover and develop CRISPR/Cas9-based therapeutic products for an additional five in vivo liver targets, for a total of up to 15 targets.

Regeneron will pay potential royalties and milestone payments for the in vivo products it independently develops. Regeneron will also receive a royalty-bearing, non-exclusive license to certain Intellia intellectual property to develop and commercialize up to 10 ex vivo CRISPR/Cas9 products in defined cell types.

 

Write to Chris Wack at chris.wack@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
INTELLIA THERAPEUTICS, INC. -1.44% 24.57 Delayed Quote.69.94%
REGENERON PHARMACEUTICALS 0.05% 640.63 Delayed Quote.70.54%
share with twitter share with LinkedIn share with facebook
Latest news on INTELLIA THERAPEUTICS, INC
06/19INTELLIA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holder..
AQ
06/08INTELLIA THERAPEUTICS : Announces Closing of $115 Million Public Offering of Com..
AQ
06/05Intellia Therapeutics Announces Closing of $115 Million Public Offering of Co..
GL
06/03INTELLIA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other ..
AQ
06/02Intellia Therapeutics Announces Pricing of Public Offering of Common Stock
GL
06/01Intellia Therapeutics Announces Proposed Public Offering of Common Stock
GL
06/01INTELLIA THERAPEUTICS : Shares Up 15% After Regeneron Expands Collaboration
DJ
06/01REGENERON PHARMACEUTICALS : Pharma, Intellia Expand Collaboration Deal
DJ
06/01INTELLIA THERAPEUTICS : Regeneron and Intellia Therapeutics Expand Collaboration..
PU
06/01INTELLIA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregi..
AQ
More news
Financials (USD)
Sales 2020 38,0 M - -
Net income 2020 -143 M - -
Net cash 2020 160 M - -
P/E ratio 2020 -9,00x
Yield 2020 -
Capitalization 1 417 M 1 417 M -
EV / Sales 2019
EV / Sales 2020 33,1x
Nbr of Employees 270
Free-Float 82,6%
Chart INTELLIA THERAPEUTICS, INC.
Duration : Period :
Intellia Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTELLIA THERAPEUTICS, INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 28,65 $
Last Close Price 24,57 $
Spread / Highest target 134%
Spread / Average Target 16,6%
Spread / Lowest Target -34,9%
EPS Revisions
Managers
NameTitle
John M. Leonard President, Chief Executive Officer & Director
Frank A. G. M. Verwiel Chairman
Andrew D. Schiermeier Chief Operating Officer
Glenn Goddard Executive VP, Chief Financial & Accounting Officer
Laura Sepp-Lorenzino Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
INTELLIA THERAPEUTICS, INC.69.94%1 438
LONZA GROUP49.26%41 725
CELLTRION, INC.79.01%34 856
SEATTLE GENETICS, INC.53.62%30 385
IQVIA HOLDINGS INC.-6.69%27 531
MODERNA, INC.214.83%23 944